Imugene

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Macquarie Group Limited

MQG

Macquarie Group Ltd. operates as a non-operating holding company. The company is headquartered in Sydney, New South Wales and currently employs 20,053 full-time employees. The company went IPO on 2007-11-05. The firm specializes in asset management, retail and business banking, wealth management, leasing and asset financing, market access, commodity trading, renewables development, specialist advice, access to capital and principal investment. Its segments include Macquarie Asset Management (MAM), Banking and Financial Services (BFS), Commodities and Global Markets (CGM) and Macquarie Capital. MAM segment provides investment solutions to clients across a range of capabilities in private markets and public investments. The BFS segment provides a range of personal banking, wealth management, and business banking products and services to retail clients, advisers, brokers, and business clients. The CGM segment is a global business offering capital and financing, risk management, market access, physical execution, and logistics solutions. Macquarie Capital segment offers advisory and capital raising services.

Vanguard All-World Ex-US Shares Index ETF

VEU

VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax

CSL

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,398 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Invictus Energy Ltd

IVZ

Invictus Energy Ltd. Engages in the exploration and appraisal of Cabora Bassa Project. The company is headquartered in Perth, Western Australia. The company went IPO on 2012-01-19. The firm is focused on energy resources in sub-Saharan Africa. Its asset portfolio consists of 360,000 hectares within the Cabora Bassa Basin in Zimbabwe, SG 4571 and EPOs 1848/49 contain the Mukuyu and multiple Basin Margin prospects. SG 4571 covers approximately 250,000 acres located in the prospective portion of the Cabora Bassa Basin in northern Zimbabwe. SG 4571 and EPOs 1848/49 contain the Mukuyu and multiple Basin Margin prospects. The Company’s subsidiaries include HIS Texas LLC, Invictus Energy Resources Pty Limited, Invictus Energy Mauritius Limited, Invictus Energy Resources Zimbabwe (Pvt) Ltd, Geo Associates (Pvt) Ltd, Miombo Forest Carbon Investments Pty Ltd, Miombo Forest Carbon Investments Mauritius Ltd, and Miombo Forest Carbon Investments Zimbabwe (Pvt) Ltd.